Correspondence

Establishing a relationship between clinical features and one specific type of chromosome abnormality

We read the article by Thillainathan and colleagues published in this Journal. The authors provided descriptive analysis of children in Sri Lankan who underwent cytogenetic analysis for suspected chromosomal disorders. They compared their results with that in Caucasian and other Asian populations. This is an important document in that the authors added their data of Sri Lanka to the international pool of these types of surveys. However, further analyses may benefit the impact of the current study.

The authors presented the cytogenetic outcomes in detail, but did not make an attempt to establish any possible linkage between clinical features and one specific type of chromosome abnormality. We know that signs and symptoms at presentation of some disorders may be non-specific. The clinicians and researchers try to summarize a relationship between some clinical symptoms and a specific chromosomal abnormality, just like some syndromes, i.e. a group of phenotypic symptoms in 22q11 micro-deletion syndrome. This database will benefit the clinical diagnosis greatly, and help the medical professionals to decide whether cytogenetic analysis is, or is not necessary for certain clinical features. In addition, the researchers can do more work on the genotype and phenotype for a specific type of chromosome abnormality, and also add more evidences to the database. Therefore, this is a valuable topic requiring further researches to illustrate the possible associations, and we highly recommend the authors to do deeper analysis focusing on it.

One of the limitation of the article is that the authors did not mention that if the parents of the children confirmed with chromosomal abnormalities participated into the analysis. Was the abnormality found in the child also found in the parents? For many chromosome abnormalities, parents may be carriers. It was also interesting if the parents had similar clinical manifestations to the child, with which we could know more about the relationship of genotype and phenotype for one certain abnormality, and confirm this association. We think the present analysis reflects the influence of experience of clinicians on making clinical diagnosis of suspected chromosome disorders.

In all, this is an important article in this field, but should do further analysis to benefit clinicians more.

Xiu-Juan Yang
Department of Pediatrics,
The First Affiliated Hospital of Zhejiang Chinese Medical University,
Hangzhou, China
Email: 13616710904@163.com

References

doi: 10.1007/s12519-016-0006-1

We agree with the reader's comments that the availability of clinical features would benefit the clinical diagnosis greatly, and help the medical professionals to decide whether cytogenetic analysis is, or is not necessary for certain clinical features. However, the main aim of our study was to describe the frequency of various types of chromosomal abnormalities in Sri Lankan children undergoing cytogenetic analysis since there was paucity of data in this field. The clinical diagnosis of suspected chromosomal disorders was made by the referring clinicians and patients were referred to us for cytogenetic confirmation of the underlying chromosomal abnormalities. We therefore did not make an attempt to establish possible linkages between the clinical features and specific types of chromosomal abnormalities in all the cases, but rather documented the pattern of cytogenetic abnormalities seen in those referred for suspected chromosomal abnormalities.

Regarding karyotyping the parents of the children, we have dealt with it in the methods section, briefly it is routine practice in our lab to karyotype the parents when...
a structural chromosomal abnormality is found. As can be seen from the karyotypes reported in Table 3 of our article;[1] the karyotypes of those with an unbalanced structural chromosomal abnormality inherited from a carrier parent with the balanced structural abnormality are designated as either "mat" or "pat".

In future studies, we hope to further analyze the genotype and phenotype correlation of specific types of chromosome abnormalities, and add more clinical evidence to the existing database to benefit the clinicians more. Some of these have already been published.[2-4]

Nirmala Sirisena, Vajira H.W. Dissanayake
Human Genetics Unit, Faculty of Medicine,
University of Colombo, Sri Lanka
Email: nirmala@anat.cmb.ac.lk; vajira@anat.cmb.ac.lk

References

doi: 10.1007/s12519-016-0007-0

Tripterygium wilfordii Hook F is efficacious in the treatment of Henoch-Schönlein purpura nephritis in children

I read with interest the recently published article by Huang et al.[1] The article is very informative and has brought an utmost important insight on chronic glomerulonephritis in children. It is an interesting issue, because glomerulonephritis such as Schönlein-Henoch nephritis (HSPN) may lead to renal failure in children and adolescents. The well-presented clinical features and histopathological changes described in the article are valuable for pediatricians in diagnosing HSPN in the high-risk population.

Huang et al[1] reported nine HSPN patients with the severest histopathological changes. They were classified as the International Study of Kidney Disease in Children (ISKDC) grade VI, and all had moderate to heavy proteinuria; all the patients in that series recovered well after treatment. Their treatment protocol is an imperative hint for managing HSPN patients. We found that 7/9 patients were given oral tripterygium glycosides; and the authors especially stressed in the methods section that tripterygium glycosides was only used in China. As they stated that tripterygium glycosides has been widely used in China as an effective immunosuppressant. It has been used for the treatment of glomerulonephritis for more than 30 years with dramatic antiproteinuric effects.[5-6] Disappointingly, they did not provide more information on tripterygium glycosides use for treatment of glomerulonephritis in the discussion section.

To our knowledge, tripterygium glycosides is the major active component of tripterygium wilfordii Hook F, which was firstly used in the nephritis treatment in 1977 by Li et al.[2] Tripterygium glycosides has been used in more than 100 000 patients in his institute.[6] It has been proven with multi-immunosuppress efficacy but with less side-effects than other immunosuppressant agents in animal and cell researches. Randomized-controlled studies have been carried out in adults. Due to the ethical issues, no clinical trials have been carried out in children; however, a nearly forty-year clinical experience in China has shown that this agent is safe, economical and efficacious for treating nephritis diseases in children. Therefore, we think that the author should introduce more information in the discussion section; the experience of treating severe HSPN patients will be helpful for pediatricians and nephrologists worldwide.

Shu-Jiong Mao, Xian-Mei Huang
Department of Pediatrics,
Hangzhou First People’s Hospital, Hangzhou, China
Email: maoshujiong@126.com

References
4 Chen ZH, Qin WS, Zeng CH, Zheng CX, Hong YM, Lu YZ, et al. Triptolide reduces proteinuria in experimental membranous...